|Bid||54.10 x 1000|
|Ask||54.14 x 900|
|Day's Range||52.97 - 54.86|
|52 Week Range||33.40 - 87.45|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.86|
LivaNova PLC announced Thad Huston, CFO, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern.
LivaNova PLC presented the first data from the Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study.
LivaNova PLC announced publication of a new study that showed positive impact from VNS Therapy for treatment-resistant bipolar depression.
LivaNova will present findings from its Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at AATS.
LivaNova announced Damien McDonald, CEO, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time.
The quarterly results for LivaNova PLC (NASDAQ:LIVN) were released last week, making it a good time to revisit its...
Joining me on today's call are Damien McDonald, our chief executive officer; Thad Huston, our chief financial officer; and Melissa Farina, our vice president of investor relations. After my comments, Thad will provide you with additional detail on the financials and our revised 2020 guidance.
Shares of LivaNova (NASDAQ:LIVN) were unchanged at $56.37 after the company reported Q1 results.Quarterly Results Earnings per share decreased 38.89% over the past year to $0.33, which missed the estimate of $0.43.Revenue of $242,400,000 lower by 3.35% year over year, which missed the estimate of $244,100,000.Guidance LivaNova hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: Apr 29, 2020View more earnings on LIVNTime: 08:05 AM ETWebcast URL: https://edge.media-server.com/mmc/p/hrqp7xshRecent Stock Performance 52-week high: $87.45Company's 52-week low was at $33.40Price action over last quarter: down 18.17%Company Profile U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.See more from Benzinga * Alkermes: Q1 Earnings Insights * Recap: Saia Q1 Earnings * Sensient Technologies: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
LivaNova (LIVN) delivered earnings and revenue surprises of -2.94% and 3.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova announced many of its cardiopulmonary products are permitted for use in the U.S. for COVID-19 ECMO use greater than 6 hours per FDA guidance.
LivaNova PLC will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m. London time (8 a.m. EDT).
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
LivaNova will share two abstracts focused on implantable neuromodulation technology for patients with heart failure during ACC.20/WCC Virtual.
LivaNova PLC today announced its VNS Therapy® System, Symmetry™, earned CE Mark approval for Difficult-to-Treat Depression.
LivaNova (LIVN) delivered earnings and revenue surprises of 5.26% and -1.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / February 26, 2020 / LivaNova PLC (NASDAQ:LIVN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 26, 2020 at 8:00 AM ...
It hasn't been the best quarter for LivaNova PLC (NASDAQ:LIVN) shareholders, since the share price has fallen 13% in...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
LivaNova Plc said on Wednesday it would stop developing its minimally-invasive mitral heart valve device and restructure its heart valve unit after years of declining sales. The company is racing with firms such as Medtronic Plc to launch the first transcatheter mitral valve replacement (TMVR) device that can help patients avoid traditional open-heart surgeries through the use of a catheter or tube to replace the valve. The UK-based company said the restructuring of its heart valve business, which brought in nearly $130 million in 2018 sales or about 11% of total revenue, could impact about 150 employees in three of its plants and would also eliminate operational overlap.
LivaNova (LIVN) delivered earnings and revenue surprises of 16.67% and -1.55%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?